Fig. 7

(Arg)₉-GST SH2 TrM resulted in apoptosis and inhibited proliferation of B16F10 cells in vivo. a Effect of (Arg)₉-GST SH2 TrM on the growth of B16F10 tumors. The changes of tumor volumes were shown between (Arg)₉-GST SH2 TrM and PBS control (n = 3, *P < 0.05). b Tumors were resected after 30 days of treatment. Tumor volumes from (Arg)₉-GST SH2 TrM group were smaller than the PBS group. c HE staining of xenograft tumors from mice injected with (Arg)₉-GST SH2 TrM (left) or PBS (right). (Arg)₉-GST SH2 TrM resulted in high level of necrosis lesions in tumors. Scale bar: 50 μm. d TUNEL assay for B16F10 tumors after treated with or without (Arg)₉-GST SH2 TrM. The apoptotic nuclei were stained with a fluorescent marker (green). Scale bar: 50 μm. e Degradation of (Arg)₉-GST SH2 TrM in normal mouse serum was evaluated by Western Blot with anti-GST antibody. f and g Tumors were resected and lysated at different time points after the injection of (Arg)₉-GST SH2 TrM protein. The level of GST-fused proteins in tumor tissue was examined by Western Blot with anti-GST antibody (f). The phosphorylation level of tyrosine proteins in tumor tissue was checked by Western Blot with anti-pY antibody. All images shown are representative of at least three independent experiments